Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,253.60 | 25.70 | -0.28% |
| CAC 40 | 7,974.85 | 3.07 | 0.04% |
| DAX 40 | 24,385.78 | 7.49 | 0.03% |
| Dow JONES (US) | 46,602.98 | 91.99 | -0.20% |
| FTSE 100 | 9,483.58 | 4.44 | 0.05% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,788.36 | 153.30 | -0.67% |
| Nikkei 225 | 47,950.88 | 6.12 | 0.01% |
| NZX 50 Index | 13,526.31 | 4.98 | -0.04% |
| S&P 500 | 6,714.59 | 25.69 | -0.38% |
| S&P/ASX 200 | 8,956.80 | 19.10 | -0.21% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |